Form 4: Nexien BioPharma CFO Evan L. Wasoff Reports Acquisition of 2,000,000 Shares

Nexien BioPharma's CFO, Evan L. Wasoff, reports acquiring 2,000,000 shares of common stock and discloses holdings of derivative securities.

Summary

• On May 23, 2024, Evan L. Wasoff, the Chief Financial Officer of Nexien BioPharma, Inc. (NXEN), acquired 2,000,000 shares of common stock.
• These shares were issued in lieu of compensation for services.
• Following the transaction, Wasoff directly owns 6,500,000 shares of common stock.
• Wasoff also holds options to purchase common stock, including 1,500,000 shares at an exercise price of $0.08, expiring on August 19, 2027, 420,000 shares at $0.54 expiring on July 25, 2025, and 200,000 shares at $0.655 expiring on October 26, 2025.

Sentiment

Score: 6

Explanation: Neutral sentiment. The filing is a routine disclosure of stock transactions. The acquisition of shares by the CFO is a mildly positive signal, but not significantly impactful on its own.

Positives

• The acquisition of shares by the CFO could be seen as a positive sign, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge management's sentiment and confidence in the company.

Comparison to Industry Standards

• Comparing the option exercise prices and expiration dates to those of similar biotech companies can provide insights into the attractiveness of Nexien BioPharma's equity compensation structure.
• For example, companies like Amgen or Gilead Sciences have different option structures based on their market capitalization and growth stage.
• A smaller company like Madrigal Pharmaceuticals might have option grants with similar exercise prices but different vesting schedules.

Stakeholder Impact

• The acquisition of shares by the CFO may have a slightly positive impact on shareholder sentiment.
• Employees may view the CFO's increased stake in the company as a sign of confidence in its future.

Key Dates

Keywords

Form 4, Beneficial Ownership, NXEN, Nexien BioPharma, Evan L. Wasoff, CFO, Stock Options, Common Stock, Acquisition